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Introduction
Mevalonate kinase deficiency (MKD) is a rare autoin-
flammatory disease, caused by mutations in the isopre-
noid pathway that lead to fever episodes. Approximately
300 MKD patients are known.
Objectives
Our objective is to describe the clinical features and
therapeutic response in a large group of MKD patients,
in order to increase knowledge of this rare disease.
Methods
The Eurofever registry (EAHC Project No. 2007332) is
retrospectively collecting clinical information on anon-
ymized patients affected by autoinflammatory diseases.
Cases were independently validated by an MKD expert.
Results
Eighty-two patients harbouring two MVK mutations and
three patients with one MVK mutation in combination
with elevated urinary excretion of mevalonic acid were
used for analysis. The group consisted of 39 males and
46 females. Median age at onset was 6 months; in 60
patients (70.6%) the disease started within the first year.
Median disease duration at enrolment in the registry
was 13.1 years. The majority of patients were Caucasian.
The most frequent mutation was V377I, occurring in 70
patients, including 12 patients that were homozygous
for this mutation. I268T was the second most frequent
mutation (n = 23). The majority of patients (75 of 85)
had a recurrent disease course. The median duration of
a fever episode was 5 days, 80.8% had a duration of 3 to
7 days. Median attack frequency was 12 per year. Trig-
gers for disease activation were known in 38 patients
and included vaccination (n = 28), stress (n = 20) and
infection (n = 12). Nearly all patients (83 of 85) suffered
from gastrointestinal symptoms, mainly diarrhea (n =
66), abdominal pain (n = 65) and vomiting (n = 51).
Seventy-one patients had cervical lymphadenopathy.
Mucocutaneous symptoms included aphthous stomatitis
(n = 47), maculopapular rash (n = 31) and pharyngitis
(n = 34). Arthralgia (n = 59) and myalgia (n = 47) were
more prominent than arthritis (n = 27). Many patients
display malaise (n = 47), fatigue (n = 50) and weight
loss (n = 44), sometimes independent of fever attacks.
IgD-levels were increased in 42 of 61 tested patients and
urinary mevalonic acid excretion was increased in 27 of
28 tested patients. Non-steroidal anti-inflammatory
drugs (NSAIDs) were mainly given during attacks and
relieved symptoms in 33 of 46 patients, including
5 patients who noted complete suppression of inflam-
matory symptoms. A complete response on corticoster-
oids was seen in 13 of 48 patients (all used during
attacks), another 29 patients reported improvement.
Anakinra was completely effective in 5 of 26 patients
and partially effective in 17 others. Etanercept was used
by 19 patients, one patient reported complete response,
11 patients some improvement; failure was noted in 7
patients. Statins failed or worsened disease in 7 patients,
4 patients reported some improvement.
Conclusion
This study describes the clinical characteristics and
response to therapy in a large international cohort of
MKD patients.Paediatric Rheumatology International Trials Organisation (PRINTO), EurofeverProject, Genoa, Italy
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